One-year metabolic outcomes in patients with type 2 diabetes treated with exenatide in routine practice.

Buysschaert M, Preumont V, Oriot PR, Paris I, Ponchon M, Scarnière D, Selvais P

Diabetes & metabolism2 Jul 2010Cited by 55 (Europe PMC)

PMID20598606DOI10.1016/j.diabet.2010.03.009PepBankPUB-20598606

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

14 results from studies that gave the peptide. 14 results from people.

01HumanObservational studySafety outcome
In routine-care patients with type 2 diabetes, 33% reported side effects, mainly gastrointestinal, during exenatide treatment.
In plain wordsIn patients with diabetes receiving routine care, 33% reported side effects, mainly digestive symptoms, during exenatide treatment.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableSide effects
Study
n = 284
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated
Measurements
Side effects
33%
safety cohort
Patients with side effects
93 patients
safety cohort
Source sentences
Summary
Side effects, mainly of gastrointestinal origin, were reported in 33% (93/284 patients in the safety cohort).
2 context sentences(design, population, supporting numbers)
Summary · context
The study objective was to analyze, in everyday practice, the long-term metabolic effects of exenatide (for 9 and 12 months) in patients with type 2 diabetes not responding to treatments with metformin and sulphonylurea at maximum dosages.
Summary · context
Two patient cohorts were analyzed for effectiveness, with data available at 9 (n=90) and 12 (n=94) months of follow-up.
Report a problemFND-2059860609
02HumanObservational studyEfficacy outcome
In routine-care patients with type 2 diabetes, HbA1c fell by 1.6% from baseline during exenatide treatment at 12 months.
In plain wordsIn patients with diabetes receiving routine care, HbA1c fell by 1.6% from baseline during exenatide treatment at 12 months.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseHbA1c at 12 months
Study
n = 94
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Measurements
HbA1c change
−1.6%
12-month cohort
Source sentences
Summary
Significant decreases in HbA(1c) of -1.3% and -1.6% were observed in the 9- and 12-month cohorts, respectively (P<0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
The study objective was to analyze, in everyday practice, the long-term metabolic effects of exenatide (for 9 and 12 months) in patients with type 2 diabetes not responding to treatments with metformin and sulphonylurea at maximum dosages.
Summary · context
Two patient cohorts were analyzed for effectiveness, with data available at 9 (n=90) and 12 (n=94) months of follow-up.
Report a problemFND-2059860602
03HumanObservational studyEfficacy outcome
In routine-care patients with type 2 diabetes, HbA1c fell by 1.3% from baseline during exenatide treatment at 9 months.
In plain wordsIn patients with diabetes receiving routine care, HbA1c fell by 1.3% from baseline during exenatide treatment at 9 months.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseHbA1c at 9 months
Study
n = 90
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 9 monthsAs given in this study (human).
Measurements
HbA1c change
−1.3%
9-month cohort
Source sentences
Summary
Significant decreases in HbA(1c) of -1.3% and -1.6% were observed in the 9- and 12-month cohorts, respectively (P<0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
The study objective was to analyze, in everyday practice, the long-term metabolic effects of exenatide (for 9 and 12 months) in patients with type 2 diabetes not responding to treatments with metformin and sulphonylurea at maximum dosages.
Summary · context
Two patient cohorts were analyzed for effectiveness, with data available at 9 (n=90) and 12 (n=94) months of follow-up.
Report a problemFND-2059860601
04HumanObservational studyOther
Among routine-care patients who discontinued exenatide, 53% discontinued mainly because of drug inefficacy.
In plain wordsAmong patients who discontinued exenatide, 53% discontinued mainly because the drug did not work.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableDiscontinuation due to inefficacy
Study
n = 77
Outcome group
Treatment adherence and retention · Whole body
Studied dose
Dose not stated
Measurements
Inefficacy discontinuation
53%
77 discontinuations
Inefficacy discontinuation
41 patients
77 discontinuations
Source sentences
Summary
Treatment was discontinued in 27% of patients (n=77) mainly due to drug inefficacy (53%, n=41) or adverse events (26%, n=20), or both (8%, n=6).
2 context sentences(design, population, supporting numbers)
Summary · context
The study objective was to analyze, in everyday practice, the long-term metabolic effects of exenatide (for 9 and 12 months) in patients with type 2 diabetes not responding to treatments with metformin and sulphonylurea at maximum dosages.
Summary · context
Two patient cohorts were analyzed for effectiveness, with data available at 9 (n=90) and 12 (n=94) months of follow-up.
Report a problemFND-2059860612
05HumanObservational studySafety outcome
Among routine-care patients who discontinued exenatide, 26% discontinued mainly because of adverse events.
In plain wordsAmong patients who discontinued exenatide, 26% discontinued mainly because of side effects.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableDiscontinuation due to adverse events
Study
n = 77
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated
Measurements
Adverse event discontinuation
26%
77 discontinuations
Adverse event discontinuation
20 patients
77 discontinuations
Source sentences
Summary
Treatment was discontinued in 27% of patients (n=77) mainly due to drug inefficacy (53%, n=41) or adverse events (26%, n=20), or both (8%, n=6).
2 context sentences(design, population, supporting numbers)
Summary · context
The study objective was to analyze, in everyday practice, the long-term metabolic effects of exenatide (for 9 and 12 months) in patients with type 2 diabetes not responding to treatments with metformin and sulphonylurea at maximum dosages.
Summary · context
Two patient cohorts were analyzed for effectiveness, with data available at 9 (n=90) and 12 (n=94) months of follow-up.
Report a problemFND-2059860613
06HumanObservational studySafety outcome
Among routine-care patients who discontinued exenatide, 8% discontinued because of both inefficacy and adverse events.
In plain wordsAmong patients who discontinued exenatide, 8% discontinued because of both lack of benefit and side effects.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableDiscontinuation due to inefficacy and adverse events
Study
n = 77
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated
Measurements
Combined reason discontinuation
8%
77 discontinuations
Combined reason discontinuation
6 patients
77 discontinuations
Source sentences
Summary
Treatment was discontinued in 27% of patients (n=77) mainly due to drug inefficacy (53%, n=41) or adverse events (26%, n=20), or both (8%, n=6).
2 context sentences(design, population, supporting numbers)
Summary · context
The study objective was to analyze, in everyday practice, the long-term metabolic effects of exenatide (for 9 and 12 months) in patients with type 2 diabetes not responding to treatments with metformin and sulphonylurea at maximum dosages.
Summary · context
Two patient cohorts were analyzed for effectiveness, with data available at 9 (n=90) and 12 (n=94) months of follow-up.
Report a problemFND-2059860614
07HumanObservational studyOther
In exenatide-treated patients, HbA1c decreased more with higher baseline HbA1c, while response was independent of weight, BMI, age, gender and diabetes duration.
In plain wordsIn exenatide-treated patients, blood sugar responses were greater with higher starting HbA1c and independent of weight, BMI, age, gender and diabetes duration.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableHbA1c response and baseline characteristics
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
The decrease in HbA(1c) was greater in patients with higher baseline levels (P<0.001), and the response was independent of baseline weight, body mass index (BMI), age, gender and diabetes duration.
2 context sentences(design, population, supporting numbers)
Summary · context
The study objective was to analyze, in everyday practice, the long-term metabolic effects of exenatide (for 9 and 12 months) in patients with type 2 diabetes not responding to treatments with metformin and sulphonylurea at maximum dosages.
Summary · context
Two patient cohorts were analyzed for effectiveness, with data available at 9 (n=90) and 12 (n=94) months of follow-up.
Report a problemFND-2059860603
08HumanObservational studyEfficacy outcome
In routine-care patients with type 2 diabetes, progressive weight reduction of 4.9 kg was observed during exenatide treatment.
In plain wordsIn patients with diabetes receiving routine care, progressive weight loss of 4.9 kg occurred during exenatide treatment.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseWeight loss
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 9 and 12 monthsAs given in this study (human).
Measurements
Weight reduction
4.9 kg
9- and 12-month cohorts
Source sentences
Summary
A progressive reduction of weight (4.9 kg) was also observed in the two cohorts at 9 and 12 months (P<0.001), with greater weight loss in patients with higher baseline BMI (P=0.046) and in female subjects (P=0.025).
2 context sentences(design, population, supporting numbers)
Summary · context
The study objective was to analyze, in everyday practice, the long-term metabolic effects of exenatide (for 9 and 12 months) in patients with type 2 diabetes not responding to treatments with metformin and sulphonylurea at maximum dosages.
Summary · context
Two patient cohorts were analyzed for effectiveness, with data available at 9 (n=90) and 12 (n=94) months of follow-up.
Report a problemFND-2059860604
09HumanObservational studyOther
In exenatide-treated patients with type 2 diabetes, greater weight loss was linked to higher baseline BMI.
In plain wordsIn exenatide-treated patients with diabetes, greater weight loss was linked to higher starting BMI.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableWeight loss and baseline BMI
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
A progressive reduction of weight (4.9 kg) was also observed in the two cohorts at 9 and 12 months (P<0.001), with greater weight loss in patients with higher baseline BMI (P=0.046) and in female subjects (P=0.025).
2 context sentences(design, population, supporting numbers)
Summary · context
The study objective was to analyze, in everyday practice, the long-term metabolic effects of exenatide (for 9 and 12 months) in patients with type 2 diabetes not responding to treatments with metformin and sulphonylurea at maximum dosages.
Summary · context
Two patient cohorts were analyzed for effectiveness, with data available at 9 (n=90) and 12 (n=94) months of follow-up.
Report a problemFND-2059860605
10HumanObservational studyOther
In exenatide-treated patients with type 2 diabetes, female gender was linked to greater weight loss.
In plain wordsIn exenatide-treated patients with diabetes, female gender was linked to greater weight loss.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableWeight loss and gender
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
A progressive reduction of weight (4.9 kg) was also observed in the two cohorts at 9 and 12 months (P<0.001), with greater weight loss in patients with higher baseline BMI (P=0.046) and in female subjects (P=0.025).
2 context sentences(design, population, supporting numbers)
Summary · context
The study objective was to analyze, in everyday practice, the long-term metabolic effects of exenatide (for 9 and 12 months) in patients with type 2 diabetes not responding to treatments with metformin and sulphonylurea at maximum dosages.
Summary · context
Two patient cohorts were analyzed for effectiveness, with data available at 9 (n=90) and 12 (n=94) months of follow-up.
Report a problemFND-2059860606
11HumanObservational studyEfficacy outcome
In routine-care patients with type 2 diabetes, waist circumference decreased from baseline during exenatide treatment.
In plain wordsIn patients with diabetes receiving routine care, waist size decreased from baseline during exenatide treatment.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseWaist circumference
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Waist circumference also decreased from baseline to endpoints.
2 context sentences(design, population, supporting numbers)
Summary · context
The study objective was to analyze, in everyday practice, the long-term metabolic effects of exenatide (for 9 and 12 months) in patients with type 2 diabetes not responding to treatments with metformin and sulphonylurea at maximum dosages.
Summary · context
Two patient cohorts were analyzed for effectiveness, with data available at 9 (n=90) and 12 (n=94) months of follow-up.
Report a problemFND-2059860607
12HumanObservational studyOther
In exenatide-treated patients with type 2 diabetes, HbA1c reduction was linked to weight loss.
In plain wordsIn exenatide-treated patients with diabetes, HbA1c reduction was linked to weight loss.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableHbA1c reduction and weight loss correlation
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
A correlation was observed between reduction in HbA(1c) and weight loss (P=0.019).
2 context sentences(design, population, supporting numbers)
Summary · context
The study objective was to analyze, in everyday practice, the long-term metabolic effects of exenatide (for 9 and 12 months) in patients with type 2 diabetes not responding to treatments with metformin and sulphonylurea at maximum dosages.
Summary · context
Two patient cohorts were analyzed for effectiveness, with data available at 9 (n=90) and 12 (n=94) months of follow-up.
Report a problemFND-2059860608
13HumanObservational studySafety outcome
In routine-care patients with type 2 diabetes, hypoglycaemia was reported at 3.5% during exenatide treatment.
In plain wordsIn patients with diabetes receiving routine care, low blood sugar was reported at 3.5% during exenatide treatment.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableHypoglycaemia
Study
n: not reported in source
Outcome group
Adverse events · Metabolic and weight
Studied dose
Dose not stated
Measurements
Hypoglycaemia
3.5%
exenatide-treated patients
Source sentences
Summary
The rate of hypoglycaemia was 3.5%.
2 context sentences(design, population, supporting numbers)
Summary · context
The study objective was to analyze, in everyday practice, the long-term metabolic effects of exenatide (for 9 and 12 months) in patients with type 2 diabetes not responding to treatments with metformin and sulphonylurea at maximum dosages.
Summary · context
Two patient cohorts were analyzed for effectiveness, with data available at 9 (n=90) and 12 (n=94) months of follow-up.
Report a problemFND-2059860610
14HumanObservational studyOther
In routine-care patients with type 2 diabetes, 27% discontinued exenatide treatment.
In plain wordsIn patients with diabetes receiving routine care, 27% discontinued exenatide treatment.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableTreatment discontinuation
Study
n: not reported in source
Outcome group
Treatment adherence and retention · Whole body
Studied dose
Dose not stated
Measurements
Discontinuation
27%
exenatide-treated patients
Discontinuations
77 patients
exenatide-treated patients
Source sentences
Summary
Treatment was discontinued in 27% of patients (n=77) mainly due to drug inefficacy (53%, n=41) or adverse events (26%, n=20), or both (8%, n=6).
2 context sentences(design, population, supporting numbers)
Summary · context
The study objective was to analyze, in everyday practice, the long-term metabolic effects of exenatide (for 9 and 12 months) in patients with type 2 diabetes not responding to treatments with metformin and sulphonylurea at maximum dosages.
Summary · context
Two patient cohorts were analyzed for effectiveness, with data available at 9 (n=90) and 12 (n=94) months of follow-up.
Report a problemFND-2059860611

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.